Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 2904-2911

  Lyngbæk, Stig ^a   Marott, Jacob L ^b   Sehestedt, Thomas ^a   Hansen, Tine W ^c,d   Olsen, Michael H ^d,g   Andersen, Ove ^e   Linneberg, Allan ^d,g   Haugaard, Steen B ^e,f   Eugen Olsen, Jesper ^e,g   Hansen, Peter R ^a   Jeppesen, Jørgen ^d,g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f Mental Health Center Glostrup   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarkers; C reactive protein; Cardiovascular risk; Framingham Risk Score; Soluble urokinase plasminogen activator receptor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UROKINASE RECEPTOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HEART DEATH; HUMAN; HUMAN EXPERIMENT; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR RISK; FRAMINGHAM RISK SCORE; SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DENMARK; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK ASSESSMENT; RISK FACTORS;

EID: 84883786878     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.07.018     Document Type: Article

References (34)

1. P. Libby Inflammation in atherosclerosis Nature 420 6917 2002 868 874
2. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207
3. J.S. Yudkin, C.D.A. Stehouwer, J.J. Emeis, and S.W. Coppack C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19 4 1999 972 978
4. P.M. Ridker, and N. Cook Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores Circulation 109 16 2004 1955 1959
5. S. Tsimikas, J.T. Willerson, and P.M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients J Am Coll Cardiol 47 8 Suppl. 2006 C19 C31
6. J. Eugen-Olsen, O. Andersen, and A. Linneberg Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population J Intern Med 268 3 2010 296 308
7. S. Lyngbaek, T. Sehestedt, and J.L. Marott CRP and suPAR are differently related to anthropometry and subclinical organ damage Int J Cardiol 167 3 2013 Aug 10 781 785
8. M. Osler, A. Linneberg, C. Glumer, and T. Jorgensen The cohorts at the Research Centre for Prevention and Health, formerly 'The Glostrup Population Studies' Int J Epidemiol 40 3 Jun 2011 602 610
9. J. Jeppesen, T.W. Hansen, and M.H. Olsen C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study Eur J Cardiovasc Prev Rehabil 15 5 2008 594 598
10. P.W. Wilson, R.B. D'Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel Prediction of coronary heart disease using risk factor categories Circulation 97 18 1998 1837 1847
11. X. Zhang, and M.J. Zhang SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models Comput Methods Programs Biomed 101 1 2011 87 93
12. D.Y. Lin, L.J. Wei, and Z. Ying Checking the Cox model with cumulative sums of martingale-based residuals Biometrika 80 3 1993 557 572
13. P.W. Wilson, B.H. Nam, M. Pencina, R.B. D'Agostino Sr., E.J. Benjamin, and C.J. O'Donnell C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study Arch Intern Med 165 21 2005 2473 2478
14. H. Uno, T. Cai, M.J. Pencina, R.B. D'Agostino, and L.J. Wei On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data Stat Med 30 10 2011 1105 1117
15. S. May, and D.W. Hosmer A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model Lifetime Data Anal 4 2 1998 109 120
16. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 1 2011 11 21
17. V. Viallon, S. Ragusa, F. Clavel-Chapelon, and J. Benichou How to evaluate the calibration of a disease risk prediction tool Stat Med 28 6 2009 901 916
18. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2 2008 157 172
19. A. Kjellman, O. Akre, and O. Gustafsson Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening J Intern Med 269 3 2011 299 305
20. M. Persson, G. Engstrom, H. Bjorkbacka, and B. Hedblad Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study Atherosclerosis 220 2 Feb 2012 502 505
21. A. Koch, S. Voigt, and C. Kruschinski Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients Crit Care 15 1 2011 R63
22. R. Huttunen, J. Syrjanen, and R. Vuento Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study J Intern Med 270 1 Jul 2011 32 40
23. T. Chavakis, A.K. Willuweit, F. Lupu, K.T. Preissner, and S.M. Kanse Release of soluble urokinase receptor from vascular cells Thromb Haemost 86 2 2001 686 693
24. B. Fevang, J. Eugen-Olsen, and A. Yndestad Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency Clin Immunol 131 3 2009 438 446
25. A.E. May, R. Schmidt, and S.M. Kanse Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction Blood 100 10 2002 3611 3617
26. S. Mustjoki, N. Sidenius, and A. Vaheri Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells FEBS Lett 486 3 2000 237 242
27. M.B. Steins, T. Padro, and C. Schwaenen Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions Blood Coagul Fibrinolysis 15 5 2004 383 391
28. T. Sehestedt, S. Lyngbaek, and J. Eugen-Olsen Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events Atherosclerosis 216 1 2011 237 243
29. C. Wei, H.S. El, and J. Li Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med 17 8 2011 952 960
30. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 19 2001 2486 2497
31. C. Rosendorff, H.R. Black, and C.P. Cannon Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 115 21 2007 2761 2788
32. R.M. Conroy, K. Pyorala, and A.P. Fitzgerald Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 11 2003 987 1003
33. L. Manzoli, W. Palumbo, P. Ruotolo, M. Panella, A. Mezzetti, and S.F. Di Cardiovascular risk of the general population assessed through SCORE and CUORE charts: an extensive survey by the general practitioners from Abruzzo, Italy Int J Cardiol 144 1 2010 47 52
34. M. Madsen, M. Davidsen, S. Rasmussen, S.Z. Abildstrom, and M. Osler The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry J Clin Epidemiol 56 2 2003 124 130